Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00689221 · ClinicalTrials.gov registry record · Phase 3
Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma and Methylated Gene Promoter Status
A Phase 3 study of Glioblastoma, sponsored by EMD Serono.
- Completed
- Registry status
- Phase 3
- Development phase
- 545
- Enrollment target
- 2
- Study locations
NCT00689221 is a Phase 3 study of Glioblastoma that has completed, run by EMD Serono. The registered enrollment target is 545 participants, above the 106-participant average among 199 other Glioblastoma trials with a reported enrollment target (414% higher). The trial reports 2 study locations across 2 states.
The verdict
NCT00689221, a Phase 3 study of Glioblastoma, has completed, sponsored by EMD Serono.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 545 participants
- Enrollment target
- 2
- Study locations
Study Summary
CENTRIC is a Phase 3 clinical trial assessing efficacy and safety of the investigational integrin inhibitor, cilengitide, in combination with standard treatment versus standard treatment alone in newly diagnosed glioblastoma subjects with a methylated O6-methylguanine-deoxyribonucleic acid methyltransferase (MGMT) gene promoter in the tumor tissue. The MGMT gene promoter is a section of deoxyribonucleic acid (DNA) that acts as a controlling element in the expression of MGMT. Methylation of the MGMT gene promoter has been found to be a predictive marker for benefit from temozolomide (TMZ) treatment.
Conditions Studied
Interventions
- DRUG Temozolomide
- RADIATION Radiotherapy
- DRUG Cilengitide
Study Locations (2)
Massachusetts
- Please Contact U.S. Medical Information Located in - Rockland
Other
- Please Contact the Merck KGaA Communication Center Located in - Darmstadt
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 545 participants |
| Start Date | 2008-09 |
| Est. Completion | 2013-08 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00689221
The ClinicalTrials.gov registry entry for NCT00689221 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 545 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 106-participant average among 199 other Glioblastoma trials with a reported enrollment target (414% higher). The listed sponsor is EMD Serono, which has 71 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Glioblastoma appearing as the primary indexed condition, and to 3 interventions - of which Temozolomide is the first listed.
NCT00689221 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Massachusetts, Other.
Frequently Asked Questions
What is clinical trial NCT00689221 about?
NCT00689221 is a clinical study titled "Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma and Methylated Gene Promoter Status". CENTRIC is a Phase 3 clinical trial assessing efficacy and safety of the investigational integrin inhibitor, cilengitide, in combination with standard treatment versus standard treatment alone in newly diagnosed glioblastoma subjects with a methylated O6-methylguanine-deoxyribonucleic acid methyltra...
What is the current status of trial NCT00689221?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 545 participants. The study started on 2008-09. Estimated completion is 2013-08.
What conditions does trial NCT00689221 study?
This clinical trial studies the following conditions: Glioblastoma.
What interventions are being tested in trial NCT00689221?
The interventions under investigation include: Temozolomide (DRUG), Radiotherapy (RADIATION), Cilengitide (DRUG).
Who is sponsoring clinical trial NCT00689221?
This trial is sponsored by EMD Serono, which has 71 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00689221 being conducted?
This trial has 2 study locations across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Glioblastoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
EF-41/KEYNOTE D58: Phase 3 Study of Optune Concomitant With Temozolomide Plus Pembrolizumab in Newly Diagnosed Glioblastoma
RECRUITING · Phase 3
-
A Study Comparing Niraparib With Temozolomide in Adult Participants With Newly-diagnosed, MGMT Unmethylated Glioblastoma
RECRUITING · Phase 3
-
Advanced Imaging Techniques for Evaluating the Tumor Immune Microenvironment in Glioblastoma Patients
RECRUITING · Phase 3
-
Repeated Superselective Intraarterial Cerebral Infusion (SIACI) of Bevacizumab With Temozolomide and Radiation Compared to Temozolomide and Radiation Alone in Newly Diagnosed GBM
RECRUITING · Phase 3
-
Beginning Radiation Immediately With GammaTile at GBM Excision Versus Standard of Care
RECRUITING · Phase 3
-
Intraoperative Radiotherapy in Newly Diagnosed Glioblastoma Multiforme
ACTIVE NOT RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.